Analysed AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ) News Sources
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
08-04-2026
yahoo.com
Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment
31-03-2026
yahoo.com
Is LUCIDITY Trial Completion in Post-Bariatric Hypoglycemia Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)?
28-03-2026
yahoo.com
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Economic Data Releases
24-03-2026
yahoo.com
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
24-03-2026
yahoo.com
Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf.
11-03-2026
marketbeat.com
Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
05-03-2026
yahoo.com
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Reduced Losses And Late Stage Pipeline Progress
04-03-2026
yahoo.com
Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout
04-03-2026
marketbeat.com
What is the current price of AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ)?
The current price of AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ) is $16.47.
AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ) absolute price change since previous trading day?
The absolute price change of AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ) since the previous trading day is $0.11.
AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ) percentage price change since previous trading day?
The percentage price change of AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ) since the previous trading day is 0.6724%.
What is the most recent average sentiment score for AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ)?
The most recent average sentiment score for AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ)?
The most recent sentiment for AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ) is .
SEC-8K** Filing Available For AMYLYX PHARMACEUTICALS INC (AMLX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.